-
1
-
-
2542641607
-
Update in atherothrombotic disease
-
Viles-Gonzalez JF, Anand SX, Valdiviezo C, Zafar MU, Hutter R, Sanz J, Rius T, Poon M, Fuster V, Badimon JJ. Update in atherothrombotic disease. Mt Sinai J Med. 2004;71(3):197-208.
-
(2004)
Mt Sinai J Med
, vol.71
, Issue.3
, pp. 197-208
-
-
Viles-Gonzalez, J.F.1
Anand, S.X.2
Valdiviezo, C.3
Zafar, M.U.4
Hutter, R.5
Sanz, J.6
Rius, T.7
Poon, M.8
Fuster, V.9
Badimon, J.J.10
-
2
-
-
35348876837
-
Review of the pleiotropic effects of peroxisome proliferator-activated receptor gamma agonists on platelet function
-
Borchert M, Schöndorf T, Lübben G, Forst T, Pfützner A. Review of the pleiotropic effects of peroxisome proliferator-activated receptor gamma agonists on platelet function. Diabetes Technol Ther. 2007;9(5):410-20.
-
(2007)
Diabetes Technol Ther
, vol.9
, Issue.5
, pp. 410-420
-
-
Borchert, M.1
Schöndorf, T.2
Lübben, G.3
Forst, T.4
Pfützner, A.5
-
3
-
-
0032484987
-
CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells
-
Henn V, Slupsky JR, Gräfe M, Anagnostopoulos I, Förster R, Müller-Berghaus G, Kroczek RA. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature. 1998;391(6667):591-4.
-
(1998)
Nature
, vol.391
, Issue.6667
, pp. 591-594
-
-
Henn, V.1
Slupsky, J.R.2
Gräfe, M.3
Anagnostopoulos, I.4
Förster, R.5
Müller-Berghaus, G.6
Kroczek, R.A.7
-
4
-
-
3042779108
-
Platelet activation, inflammatory mediators and hypercholesterolemia
-
Ferroni P, Basili S, Davi G. Platelet activation, inflammatory mediators and hypercholesterolemia. Curr Vasc Pharmacol. 2003;1(2):157-69.
-
(2003)
Curr Vasc Pharmacol
, vol.1
, Issue.2
, pp. 157-169
-
-
Ferroni, P.1
Basili, S.2
Davi, G.3
-
5
-
-
33745017446
-
Effects of improved metabolic control on platelet reactivity in patients with type 2 diabetes mellitus following coronary angioplasty
-
Yngen M, Norhammar A, Hjemdahl P, Wallén NH. Effects of improved metabolic control on platelet reactivity in patients with type 2 diabetes mellitus following coronary angioplasty. Diab Vasc Dis Res. 2006;3(1):52-6.
-
(2006)
Diab Vasc Dis Res
, vol.3
, Issue.1
, pp. 52-56
-
-
Yngen, M.1
Norhammar, A.2
Hjemdahl, P.3
Wallén, N.H.4
-
6
-
-
0043167980
-
Obesity is associated with impaired platelet-inhibitory effect of acetylsalicylic acid in nondiabetic subjects
-
Tamminen M, Lassila R, Westerbacka J, Vehkavaara S, Yki-Järvinen H. Obesity is associated with impaired platelet-inhibitory effect of acetylsalicylic acid in nondiabetic subjects. Int J Obes Relat Metab Disord. 2003;27(8):907-11.
-
(2003)
Int J Obes Relat Metab Disord
, vol.27
, Issue.8
, pp. 907-911
-
-
Tamminen, M.1
Lassila, R.2
Westerbacka, J.3
Vehkavaara, S.4
Yki-Järvinen, H.5
-
7
-
-
33644870179
-
Platelet inhibition by insulin is absent in type 2 diabetes mellitus
-
Ferreira IA, Mocking AI, Feijge MA, Gorter G, van Haeften TW, Heemskerk JW, Akkerman JW. Platelet inhibition by insulin is absent in type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol. 2006;26(2):417-22.
-
(2006)
Arterioscler Thromb Vasc Biol
, vol.26
, Issue.2
, pp. 417-422
-
-
Ferreira, I.A.1
Mocking, A.I.2
Feijge, M.A.3
Gorter, G.4
Van Haeften, T.W.5
Heemskerk, J.W.6
Akkerman, J.W.7
-
8
-
-
85039641741
-
The fixed combination of pioglitazone with metformin improves biomarkers of chronic systemic inflammation and platelet function in comparison to metformin + glimepiride. Results from the PIOfix study
-
Pfützner AH, Forst T, Löbig M, Schöndorf T, Hohberg C, Braun M, Lehmann U, Fuchs W, Pfützner A. The fixed combination of pioglitazone with metformin improves biomarkers of chronic systemic inflammation and platelet function in comparison to metformin + glimepiride. Results from the PIOfix study. Diabetes. 2010;59(Suppl 1):A200-1.
-
(2010)
Diabetes
, vol.59
, Issue.SUPPL. 1
-
-
Pfützner, A.H.1
Forst, T.2
Löbig, M.3
Schöndorf, T.4
Hohberg, C.5
Braun, M.6
Lehmann, U.7
Fuchs, W.8
Pfützner, A.9
-
9
-
-
33645277645
-
High-sensitivity C-reactive protein as cardiovascular risk marker in patients with diabetes mellitus
-
Pfützner A, Forst T. High-sensitivity C-reactive protein as cardiovascular risk marker in patients with diabetes mellitus. Diabetes Technol Ther. 2006;8(1):28-36.
-
(2006)
Diabetes Technol Ther
, vol.8
, Issue.1
, pp. 28-36
-
-
Pfützner, A.1
Forst, T.2
-
10
-
-
14744287439
-
Pathobiology and cell interactions of platelets in diabetes
-
Stratmann B, Tschoepe D. Pathobiology and cell interactions of platelets in diabetes. Diab Vasc Dis Res. 2005;2(1):16-23.
-
(2005)
Diab Vasc Dis Res
, vol.2
, Issue.1
, pp. 16-23
-
-
Stratmann, B.1
Tschoepe, D.2
-
11
-
-
33751524662
-
Platelet and monocyte activation by hyperglycemia and hyperinsulinemia in healthy subjects
-
Vaidyula VR, Boden G, Rao AK. Platelet and monocyte activation by hyperglycemia and hyperinsulinemia in healthy subjects. Platelets. 2006;17(8):577-85.
-
(2006)
Platelets
, vol.17
, Issue.8
, pp. 577-585
-
-
Vaidyula, V.R.1
Boden, G.2
Rao, A.K.3
-
12
-
-
33645678090
-
Blood platelet abnormalities and pharmacological modulation of platelet reactivity in patients with diabetes mellitus
-
Watala C, Boncler M, Gresner P. Blood platelet abnormalities and pharmacological modulation of platelet reactivity in patients with diabetes mellitus. Pharmacol Rep. 2005;57 Suppl:42-58.
-
(2005)
Pharmacol Rep
, vol.57
, Issue.SUPPL.
, pp. 42-58
-
-
Watala, C.1
Boncler, M.2
Gresner, P.3
-
13
-
-
0033485806
-
Hemodynamic shear stress and its role in atherosclerosis
-
Malek AM, Alper SL, Izumo S. Hemodynamic shear stress and its role in atherosclerosis. JAMA. 1999;282(21):2035-42.
-
(1999)
JAMA
, vol.282
, Issue.21
, pp. 2035-2042
-
-
Malek, A.M.1
Alper, S.L.2
Izumo, S.3
-
14
-
-
20444495375
-
Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: Results from the pioneer study
-
Pfützner A, Marx N, LübbenvG, Langenfeld M, Walcher D, Konrad T, Forst T. Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study. J Am Coll Cardiol. 2005;45(12):1925-31.
-
(2005)
J Am Coll Cardiol
, vol.45
, Issue.12
, pp. 1925-1931
-
-
Pfützner, A.1
Marx, N.2
Lübbenv, G.3
Langenfeld, M.4
Walcher, D.5
Konrad, T.6
Forst, T.7
-
15
-
-
56249121001
-
Rosiglitazone, but not glimepiride, improves myocardial diastolic function in association with reduction in oxidative stress in type 2 diabetic patients without overt heart disease
-
Von Bibra H, Diamant M, Scheffer PG, Siegmund T, Schumm-Draeger PM. Rosiglitazone, but not glimepiride, improves myocardial diastolic function in association with reduction in oxidative stress in type 2 diabetic patients without overt heart disease. Diab Vasc Dis Res. 2008;5(4):310-8.
-
(2008)
Diab Vasc Dis Res
, vol.5
, Issue.4
, pp. 310-318
-
-
Von Bibra, H.1
Diamant, M.2
Scheffer, P.G.3
Siegmund, T.4
Schumm-Draeger, P.M.5
-
16
-
-
0033821518
-
The influence of improved glycaemic control with insulin and sulphonylureas on acute phase and endothelial markers in type II diabetic subjects
-
Yudkin JS, Panahloo A, Stehouwer C, Emeis JJ, Bulmer K, Mohamed-Ali V, Denver AE. The influence of improved glycaemic control with insulin and sulphonylureas on acute phase and endothelial markers in type II diabetic subjects. Diabetologia 2000;43(9):1099-106.
-
(2000)
Diabetologia
, vol.43
, Issue.9
, pp. 1099-1106
-
-
Yudkin, J.S.1
Panahloo, A.2
Stehouwer, C.3
Emeis, J.J.4
Bulmer, K.5
Mohamed-Ali, V.6
Denver, A.E.7
-
17
-
-
3843140669
-
C-reactive protein, its role in inflammation, Type 2 diabetes and cardiovascular disease, and the effects of insulin-sensitizing treatment with thiazolidinediones
-
Nesto R. C-reactive protein, its role in inflammation, Type 2 diabetes and cardiovascular disease, and the effects of insulin-sensitizing treatment with thiazolidinediones. Diabet Med. 2004;21(8):810-7.
-
(2004)
Diabet Med
, vol.21
, Issue.8
, pp. 810-817
-
-
Nesto, R.1
-
18
-
-
33846273797
-
Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: The PIOSTAT Study
-
Hanefeld M, Marx N, Pfützner A, Baurecht W, Lübben G, Karagiannis E, Stier U, Forst T. Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT Study. J Am Coll Cardiol. 2007;49(3):290-7.
-
(2007)
J Am Coll Cardiol
, vol.49
, Issue.3
, pp. 290-297
-
-
Hanefeld, M.1
Marx, N.2
Pfützner, A.3
Baurecht, W.4
Lübben, G.5
Karagiannis, E.6
Stier, U.7
Forst, T.8
-
19
-
-
43549097824
-
The IRIS V study: Pioglitazone improves systemic chronic inflammation in patients with type 2 diabetes under daily routine conditions
-
Karagiannis E, Pfützner A, Forst T, Lübben G, Roth W, Grabellus M, Flannery M, Schöndorf T. The IRIS V study: pioglitazone improves systemic chronic inflammation in patients with type 2 diabetes under daily routine conditions. Diabetes Technol Ther. 2008;10(3):206-12.
-
(2008)
Diabetes Technol Ther
, vol.10
, Issue.3
, pp. 206-212
-
-
Karagiannis, E.1
Pfützner, A.2
Forst, T.3
Lübben, G.4
Roth, W.5
Grabellus, M.6
Flannery, M.7
Schöndorf, T.8
-
20
-
-
39449138164
-
Pleiotropic and anti-inflammatory effects of pioglitazone precede the metabolic activity in type 2 diabetic patients with coronary artery disease
-
Forst T, Karagiannis E, Lübben G, Hohberg C, Schöndorf T, Dikta G, Drexler M, Morcos M, Dänschel W, Borchert M, Pfützner A. Pleiotropic and anti-inflammatory effects of pioglitazone precede the metabolic activity in type 2 diabetic patients with coronary artery disease. Atherosclerosis. 2008;197(1):311-7.
-
(2008)
Atherosclerosis
, vol.197
, Issue.1
, pp. 311-317
-
-
Forst, T.1
Karagiannis, E.2
Lübben, G.3
Hohberg, C.4
Schöndorf, T.5
Dikta, G.6
Drexler, M.7
Morcos, M.8
Dänschel, W.9
Borchert, M.10
Pfützner, A.11
-
21
-
-
67649841976
-
Competact, a fixed combination of pioglitazone and metformin, improves metabolic markers in type 2 diabetes patients with insufficient glycemic control by metformin alone - Results from a post-marketing surveillance trial under daily routine conditions
-
Schöndorf T, Karagiannis E, Posseldt RE, Forst T, Pfützner A. Competact, a fixed combination of pioglitazone and metformin, improves metabolic markers in type 2 diabetes patients with insufficient glycemic control by metformin alone - results from a post-marketing surveillance trial under daily routine conditions. Diabetes Technol Ther 2009;11(6):379-83.
-
(2009)
Diabetes Technol Ther
, vol.11
, Issue.6
, pp. 379-383
-
-
Schöndorf, T.1
Karagiannis, E.2
Posseldt, R.E.3
Forst, T.4
Pfützner, A.5
-
22
-
-
84973349634
-
PIOace-Study: Pioglitazone, but not ramipril improves thrombocyte function and reduces low grade inflammation in non-diabetic patients with increased cardiovascular risk
-
Pfützner A, Hanefeld M, Afzal-Dekordi L, Müller J, Kleine I, Fuchs W, Forst T. PIOace-Study: pioglitazone, but not ramipril improves thrombocyte function and reduces low grade inflammation in non-diabetic patients with increased cardiovascular risk. Diabetologia. 2009;52 (Suppl 1):S335-6.
-
(2009)
Diabetologia
, vol.52
, Issue.SUPPL. 1
-
-
Pfützner, A.1
Hanefeld, M.2
Afzal-Dekordi, L.3
Müller, J.4
Kleine, I.5
Fuchs, W.6
Forst, T.7
-
23
-
-
34547882402
-
Reduction in hematocrit and hemoglobin following pioglitazone treatment is not hemodilutional in Type II diabetes mellitus
-
Berria R, Glass L, Mahankali A, Miyazaki Y, Monroy A, De Filippis E, Cusi K, Cersosimo E, Defronzo RA, Gastaldelli A. Reduction in hematocrit and hemoglobin following pioglitazone treatment is not hemodilutional in Type II diabetes mellitus. Clin Pharmacol Ther. 2007;82(3):275-81.
-
(2007)
Clin Pharmacol Ther
, vol.82
, Issue.3
, pp. 275-281
-
-
Berria, R.1
Glass, L.2
Mahankali, A.3
Miyazaki, Y.4
Monroy, A.5
De Filippis, E.6
Cusi, K.7
Cersosimo, E.8
Defronzo, R.A.9
Gastaldelli, A.10
-
24
-
-
2642522886
-
Soluble CD40 ligand, soluble P-selectin, interleukin-6, and tissue factor in diabetes mellitus: Relationships to cardiovascular disease and risk factor intervention
-
Lim HS, Blann AD, Lip GY. Soluble CD40 ligand, soluble P-selectin, interleukin-6, and tissue factor in diabetes mellitus: relationships to cardiovascular disease and risk factor intervention. Circulation. 2004;109(21):2524-8.
-
(2004)
Circulation
, vol.109
, Issue.21
, pp. 2524-2528
-
-
Lim, H.S.1
Blann, A.D.2
Lip, G.Y.3
-
25
-
-
4143126478
-
CD40 ligand: A novel target in the fight against cardiovsacular disease
-
Vishnevetsky D, Kiyanista VA, Gandhi PJ. CD40 ligand: a novel target in the fight against cardiovsacular disease. Ann Pharmacother. 2004;38(9):1500-8.
-
(2004)
Ann Pharmacother
, vol.38
, Issue.9
, pp. 1500-1508
-
-
Vishnevetsky, D.1
Kiyanista, V.A.2
Gandhi, P.J.3
-
26
-
-
30344483664
-
Thromboxane-dependent CD40 ligand release in type 2 diabetes mellitus
-
Santilli F, Davi G, Consoli A, Cipollone F, Mezzetti A, Falco A, Taraborelli T, Devangelio E, Ciabattoni G, Basili S, Patrono C. Thromboxane-dependent CD40 ligand release in type 2 diabetes mellitus. J Am Coll Cardiol. 2006;47(2):391-7.
-
(2006)
J Am Coll Cardiol
, vol.47
, Issue.2
, pp. 391-397
-
-
Santilli, F.1
Davi, G.2
Consoli, A.3
Cipollone, F.4
Mezzetti, A.5
Falco, A.6
Taraborelli, T.7
Devangelio, E.8
Ciabattoni, G.9
Basili, S.10
Patrono, C.11
-
27
-
-
33845331720
-
Insulin resistance as a determinant of platelet activation in obese women
-
Basili S, Pacini G, Guagnano MT, Manigrasso MR, Santilli F, Pettinella C, Ciabattoni G, Patrono C, Davi G. Insulin resistance as a determinant of platelet activation in obese women. J Am Coll Cardiol. 2006;48(12):2531-8.
-
(2006)
J Am Coll Cardiol
, vol.48
, Issue.12
, pp. 2531-2538
-
-
Basili, S.1
Pacini, G.2
Guagnano, M.T.3
Manigrasso, M.R.4
Santilli, F.5
Pettinella, C.6
Ciabattoni, G.7
Patrono, C.8
Davi, G.9
-
28
-
-
14744284119
-
Effect of rosiglitazone treatment on circulating vascular and inflammatory markers in insulin-resistant subjects
-
Chu JW, Abbasi F, Lamendola C, McLaughlin T, Reaven GM, Tsao PS. Effect of rosiglitazone treatment on circulating vascular and inflammatory markers in insulin-resistant subjects. Diab Vasc Dis Res. 2005;2(1):37-41.
-
(2005)
Diab Vasc Dis Res
, vol.2
, Issue.1
, pp. 37-41
-
-
Chu, J.W.1
Abbasi, F.2
Lamendola, C.3
McLaughlin, T.4
Reaven, G.M.5
Tsao, P.S.6
-
29
-
-
0242543997
-
The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients
-
Sidhu JS, Cowan D, Kaski JC. The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients. J Am Coll Cardiol. 2003;42(10):1757-63.
-
(2003)
J Am Coll Cardiol
, vol.42
, Issue.10
, pp. 1757-1763
-
-
Sidhu, J.S.1
Cowan, D.2
Kaski, J.C.3
-
30
-
-
24144470455
-
Rapid effects of rosiglitazone treatment on endothelial function and inflammatory biomarkers
-
Hetzel J, Balletshofer B, Rittig K, Walcher D, Kratzer W, Hombach V, Häring HU, Koenig W, Marx N. Rapid effects of rosiglitazone treatment on endothelial function and inflammatory biomarkers. Arterioscler Thromb Vasc Biol. 2005;25(9):1804-9.
-
(2005)
Arterioscler Thromb Vasc Biol
, vol.25
, Issue.9
, pp. 1804-1809
-
-
Hetzel, J.1
Balletshofer, B.2
Rittig, K.3
Walcher, D.4
Kratzer, W.5
Hombach, V.6
Häring, H.U.7
Koenig, W.8
Marx, N.9
-
31
-
-
32844469572
-
Effects of rosiglitazone alone and in combination with atorvastatin on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus
-
Chu CS, Lee KT, Lee MY, Su HM, Voon WC, Sheu SH, Lai WT. Effects of rosiglitazone alone and in combination with atorvastatin on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Am J Cardiol. 2006;97(5):646-50.
-
(2006)
Am J Cardiol
, vol.97
, Issue.5
, pp. 646-650
-
-
Chu, C.S.1
Lee, K.T.2
Lee, M.Y.3
Su, H.M.4
Voon, W.C.5
Sheu, S.H.6
Lai, W.T.7
-
32
-
-
0037461106
-
Effect of rosiglitazone treatment on soluble CD40L in patients with type 2 diabetes and coronary artery disease
-
Marx N, Imhof A, Froehlich J, Siam L, Ittner J, Wierse G, Schmidt A, Maerz W, Hombach V, Koenig W. Effect of rosiglitazone treatment on soluble CD40L in patients with type 2 diabetes and coronary artery disease. Circulation. 2003;107(15):1954-7.
-
(2003)
Circulation
, vol.107
, Issue.15
, pp. 1954-1957
-
-
Marx, N.1
Imhof, A.2
Froehlich, J.3
Siam, L.4
Ittner, J.5
Wierse, G.6
Schmidt, A.7
Maerz, W.8
Hombach, V.9
Koenig, W.10
-
33
-
-
40949098983
-
Rosiglitazone produces a greater reduction in circulating platelet activity compared with gliclazide in patients with type 2 diabetes mellitus - an effect probably mediated by direct platelet PPARgamma activation
-
Khanolkar MP, Morris RH, Thomas AW, Bolusani H, Roberts AW, Geen J, Jackson SK, Evans LM. Rosiglitazone produces a greater reduction in circulating platelet activity compared with gliclazide in patients with type 2 diabetes mellitus - an effect probably mediated by direct platelet PPARgamma activation. Atherosclerosis. 2008;197(2):718-24.
-
(2008)
Atherosclerosis
, vol.197
, Issue.2
, pp. 718-724
-
-
Khanolkar, M.P.1
Morris, R.H.2
Thomas, A.W.3
Bolusani, H.4
Roberts, A.W.5
Geen, J.6
Jackson, S.K.7
Evans, L.M.8
-
34
-
-
72649105693
-
The effect of rosiglitazone on the expression of thrombogenic markers in leukocytes in type 2 diabetes mellitus
-
Svobodová H, Stulc T, Kasalová Z, Dolezalová R, Marinov I, Capek P, Ceska R. The effect of rosiglitazone on the expression of thrombogenic markers in leukocytes in type 2 diabetes mellitus. Physiol Res. 2009;58(5):701-7.
-
(2009)
Physiol Res
, vol.58
, Issue.5
, pp. 701-707
-
-
Svobodová, H.1
Stulc, T.2
Kasalová, Z.3
Dolezalová, R.4
Marinov, I.5
Capek, P.6
Ceska, R.7
-
35
-
-
53349153475
-
Pioglitazone and cardiovascular risk. A comprehensive meta-analysis of randomized clinical trials
-
Mannucci E, Monami M, Lamanna C, Gensini GF, Marchionni N. Pioglitazone and cardiovascular risk. A comprehensive meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2008;10(12):1221-38.
-
(2008)
Diabetes Obes Metab
, vol.10
, Issue.12
, pp. 1221-1238
-
-
Mannucci, E.1
Monami, M.2
Lamanna, C.3
Gensini, G.F.4
Marchionni, N.5
-
36
-
-
78649772977
-
Effects of pioglitazone and metformin fixed-dose combination therapy on cardiovascular risk markers of inflammation and lipid profile compared with pioglitazone and metformin monotherapy in patients with type 2 diabetes mellitus
-
Greenwich
-
Perez A, Jacks R, Arora V, Spanheimer R. Effects of pioglitazone and metformin fixed-dose combination therapy on cardiovascular risk markers of inflammation and lipid profile compared with pioglitazone and metformin monotherapy in patients with type 2 diabetes mellitus. J Clin Hypertens (Greenwich). 2010;12(12):973-82.
-
(2010)
J Clin Hypertens
, vol.12
, Issue.12
, pp. 973-982
-
-
Perez, A.1
Jacks, R.2
Arora, V.3
Spanheimer, R.4
-
37
-
-
40849134281
-
Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: Results from PROspective pioglitAzone Clinical Trial In macroVascular Events (PROactive10)
-
PROactive Study Investigators
-
Wilcox R, Kupfer S, Erdmann E, PROactive Study Investigators. Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: results from PROspective pioglitAzone Clinical Trial In macroVascular Events (PROactive10). Am Heart J. 2008;155(4):712-7.
-
(2008)
Am Heart J
, vol.155
, Issue.4
, pp. 712-717
-
-
Wilcox, R.1
Kupfer, S.2
Erdmann, E.3
|